N. Lytvynenko, M. Pogrebna, L. Protsyk, Y. Senko, V. Davydenko, L. Shcherbakova, O. Chobotar
{"title":"BEST CLINICAL PRACTICE OF MANAGEMENT OF SIDE EFFECTS OF BPAL REGIMEN (CLINICAL CASE)","authors":"N. Lytvynenko, M. Pogrebna, L. Protsyk, Y. Senko, V. Davydenko, L. Shcherbakova, O. Chobotar","doi":"10.31215/2306-4927-2022-30-2-72-74","DOIUrl":null,"url":null,"abstract":"New 6-months regimen based on bedaquiline, pretomanid and linesolid (BPaL), evaluated in TB-PRACTECAL clinical trial, is one of modern treatments for extensively drug resistant tuberculosis. Patients on BPaL should be carefully observed for side effects, especially liver toxicity, myelosuppression, peripheral and optic neuropathy, QT-interval prolongation and pancreatitis. A clinical case of extensively drug resistant tuberculosis with the outcomes of BPaL regimen treatment on the backgrounds of side effects is presented in current report. This case demonstrates that timely and thorough monitoring of side effects allows to preserve the BPaL regimen modality, regardless the occurrence of several adverse effects in one person and to complete the prescribed course of treatment, which resulted in cure. Key words: extensively drug resistant tuberculosis, BPaL regimen of treatment, saide effects.","PeriodicalId":328937,"journal":{"name":"Ukrainian Pulmonology Journal","volume":"22 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ukrainian Pulmonology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31215/2306-4927-2022-30-2-72-74","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
New 6-months regimen based on bedaquiline, pretomanid and linesolid (BPaL), evaluated in TB-PRACTECAL clinical trial, is one of modern treatments for extensively drug resistant tuberculosis. Patients on BPaL should be carefully observed for side effects, especially liver toxicity, myelosuppression, peripheral and optic neuropathy, QT-interval prolongation and pancreatitis. A clinical case of extensively drug resistant tuberculosis with the outcomes of BPaL regimen treatment on the backgrounds of side effects is presented in current report. This case demonstrates that timely and thorough monitoring of side effects allows to preserve the BPaL regimen modality, regardless the occurrence of several adverse effects in one person and to complete the prescribed course of treatment, which resulted in cure. Key words: extensively drug resistant tuberculosis, BPaL regimen of treatment, saide effects.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
